Enzene Partners with Virtuosi to Forge Skilled Workforce in India

In a notable move for India's pharmaceutical landscape, Enzene Biosciences Ltd., recognized as a pioneering Continuously Innovative Development and Manufacturing Organization (CIDMO), has officially partnered with Virtuosi®, the world’s first IACET-accredited immersive training platform for pharmaceutical manufacturing. This partnership, unveiled on October 8, 2025, positions Enzene as the first Indian company to collaborate with Virtuosi, implemented by Quality Executive Partners, Inc. (QxP).

Addressing Workforce Needs in a Growing Industry

As India pushes the boundaries of innovation in biologics and biosimilars, the demand for a highly skilled workforce has surged. The pharmaceutical sector has experienced rapid growth, hence the urgency to equip professionals with the necessary knowledge and skills has never been more critical. Virtuosi offers an interactive and scalable learning platform that employs cutting-edge methods such as virtual reality (VR), digital simulations, and accredited technical curricula to enhance workforce competence in essential areas like aseptic processing, quality assurance, data integrity, and regulatory compliance.

Sundar Ramanan, PhD, the Chief Quality Officer at Enzene, emphasized the importance of this initiative. He stated, "Investing in our people and nurturing a skilled workforce are crucial for establishing ourselves as a trusted global pharmaceutical leader." By aligning with Virtuosi, Enzene not only elevates its training standards but also aims to set a high bar for the entire industry.

Vision for Manufacturing Excellence

The strategic alliance between Enzene and Virtuosi is seen as a significant step towards revolutionizing workforce training in the pharmaceutical sector. Crystal Mersh, CEO and Founder of Quality Executive Partners, acknowledged Enzene's pioneering role in this endeavor and commented, "Enzene’s leadership demonstrates vision and commitment at a time when the global industry is calling for stronger workforce readiness."

Enzene's initiative is not just limited to its internal training; it aims to create a benchmark that could impact the larger sector. The integration of Virtuosi into Enzene's workforce development programs exemplifies the organization’s commitment to fostering a culture of continuous learning. This move also reinforces India's position as a pivotal player in the global pharmaceutical manufacturing arena.

About Enzene Biosciences

Operating integrated facilities in Pune (India) and New Jersey (USA), Enzene is a fully integrated CIDMO offering a wide range of services that extend from discovery to commercial supply. With a focus on next-generation biological technologies, the company is reshaping the biologics manufacturing landscape through its patented EnzeneX™ technology. This innovation is recognized as the first fully-connected continuous manufacturing platform validated for commercial biologics supply.

Enzene collaborates with innovators and developers of biosimilars, facilitating quicker time-to-market, enhanced production yields, and significant cost reductions across various biological modalities. Their aspiration extends towards decreasing the cost of monoclonal antibody production to below $40 per gram by 2025.

About Virtuosi

Virtuosi, created by Quality Executive Partners, is the world’s first IACET-accredited interactive training platform for the pharmaceutical industry, intended to equip professionals with both practical skills and regulatory knowledge. With an impressive suite of over 100 hours of content and 26 VR segments focusing on critical subjects like aseptic processing, microbiology, and cell gene therapy, Virtuosi is adaptable and available in multiple languages to fulfill local needs across the globe.

Conclusion

As Enzene leads the charge in integrating advanced training solutions like Virtuosi into its strategies, it embodies a new era of manufacturing excellence. This collaboration not only fortifies Enzene's workforce but also aims to uplift the entire Indian pharmaceutical sector, ensuring it meets global benchmarks for quality and compliance.